Nektar Therapeutics (NKTR)

Jun 15, 2026

NKTR: 5,538 RSUs registered for resale via Morgan Stanley (NKTR) - Stock Titan

Jun 15, 2026

Jun 14, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jun 14, 2026

Jun 13, 2026

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

Jun 13, 2026

Jun 11, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jun 11, 2026

Jun 10, 2026

Nektar Therapeutics: Shareholders Board Members Managers and Company Profile | US6402683063 - marketscreener.com

Jun 10, 2026

Jun 09, 2026

NKTR News | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill

Jun 09, 2026

Jun 09, 2026

Nektar Therapeutics (NKTR) Slips 1.5% Amid Consolidation Near Key Support LevelsFloat Adjusted Cap - newsline.com

Jun 09, 2026

Jun 09, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Jun 09, 2026

Jun 08, 2026

Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program? - simplywall.st

Jun 08, 2026

Jun 07, 2026

Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Gr - The National Law Review

Jun 07, 2026

Jun 06, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility - Yahoo Finance

Jun 06, 2026

Jun 06, 2026

Inventory turnover of Nektar Therapeutics – XETR:ITH0 - TradingView

Jun 06, 2026

Jun 06, 2026

Nektar Therapeutics 8-K SEC Filing: Company Details, Common Stock, and NASDAQ Listing (June 2026) - Minichart

Jun 06, 2026

Jun 06, 2026

Diluted net income available to common stockholders of Nektar Therapeutics – XETR:ITH0 - TradingView

Jun 06, 2026

Jun 06, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Pullback - simplywall.st

Jun 06, 2026

Jun 05, 2026

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock - Insider Monkey

Jun 05, 2026

Jun 05, 2026

Nektar Therapeutics (NKTR) holders back plan share boost and auditor at 2026 meeting - Stock Titan

Jun 05, 2026

Jun 05, 2026

NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits

Jun 05, 2026

Jun 04, 2026

NKTR: All proposals passed; immunology pipeline advances with REZPEG entering phase III trials - TradingView

Jun 04, 2026

Jun 04, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - The National Law Review

Jun 04, 2026

Jun 03, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus

Jun 03, 2026

Jun 03, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jun 03, 2026

Jun 02, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review

Jun 02, 2026

Jun 01, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jun 01, 2026

May 28, 2026

Drug developers outpace Nasdaq Bio, rezpeg data sends up Nektar - BioWorld News

May 28, 2026

May 28, 2026

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York - The AI Journal

May 28, 2026

May 27, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - AOL.com

May 27, 2026

May 27, 2026

Nektar Therapeutics to webcast at 2026 Jefferies Global Healthcare Conference on June 3 - Pluang

May 27, 2026

May 27, 2026

How to watch Nektar’s Jefferies healthcare fireside chat on June 3 - Stock Titan

May 27, 2026

May 27, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Stockholders to Reach Out - ACCESS Newswire

May 27, 2026

May 26, 2026

Interim CFO at Nektar Therapeutics (NKTR) files initial Form 3 ownership report - Stock Titan

May 26, 2026

May 26, 2026

Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data (NKTR) - Seeking Alpha

May 26, 2026

May 25, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire

May 25, 2026

May 24, 2026

A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial - simplywall.st

May 24, 2026

May 23, 2026

What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch - The Motley Fool

May 23, 2026

May 22, 2026

Prosight Management Increases Stake in Nektar Therapeutics - Intellectia AI

May 22, 2026

May 22, 2026

Nektar TherapeuticsCommon Stock (NQ: NKTR - The Chronicle-Journal

May 22, 2026

May 22, 2026

NKTR Stock Price, Quote & Chart | NEKTAR THERAPEUTICS (NASDAQ:NKTR) - ChartMill

May 22, 2026

May 21, 2026

Nektar Therapeutics R&D chief sells $13,036 in shares - Investing.com UK

May 21, 2026

May 21, 2026

Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

Nektar Therapeutics R&D chief sells $13,036 in shares By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

Nektar Therapeutics CEO Robin Howard W sells $29,086 in shares - Investing.com

May 21, 2026